Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 19;18(1):124.
doi: 10.1186/s12931-017-0609-7.

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)

Sean Duffy  1   2 , Robert Marron  3 , Helen Voelker  4 , Richard Albert  5 , John Connett  4 , William Bailey  6 , Richard Casaburi  7 , J Allen Cooper Jr  6 , Jeffrey L Curtis  8 , Mark Dransfield  6 , MeiLan K Han  8 , Barry Make  9 , Nathaniel Marchetti  3 , Fernando Martinez  10 , Stephen Lazarus  11 , Dennis Niewoehner  12 , Paul D Scanlon  13 , Frank Sciurba  14 , Steven Scharf  15 , Robert M Reed  15 , George Washko  16 , Prescott Woodruff  11 , Charlene McEvoy  17 , Shawn Aaron  18 , Don Sin  19 , Gerard J Criner  3 ; NIH COPD Clinical Research Network and the Canadian Institutes of Health Research
Affiliations

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)

Sean Duffy et al. Respir Res. .

Abstract

Background: Beta-blockers are commonly prescribed for patients with cardiovascular disease. Providers have been wary of treating chronic obstructive pulmonary disease (COPD) patients with beta-blockers due to concern for bronchospasm, but retrospective studies have shown that cardio-selective beta-blockers are safe in COPD and possibly beneficial. However, these benefits may reflect symptom improvements due to the cardiac effects of the medication. The purpose of this study is to evaluate associations between beta-blocker use and both exacerbation rates and longitudinal measures of lung function in two well-characterized COPD cohorts.

Methods: We retrospectively analyzed 1219 participants with over 180 days of follow up from the STATCOPE trial, which excluded most cardiac comorbidities, and from the placebo arm of the MACRO trial. Primary endpoints were exacerbation rates per person-year and change in spirometry over time in association with beta blocker use.

Results: Overall 13.9% (170/1219) of participants reported taking beta-blockers at enrollment. We found no statistically significant differences in exacerbation rates with respect to beta-blocker use regardless of the prevalence of cardiac comorbidities. In the MACRO cohort, patients taking beta-blockers had an exacerbation rate of 1.72/person-year versus a rate of 1.71/person-year in patients not taking beta-blockers. In the STATCOPE cohort, patients taking beta-blockers had an exacerbation rate of 1.14/person-year. Patients without beta-blockers had an exacerbation rate of 1.34/person-year. We found no detrimental effect of beta blockers with respect to change in lung function over time.

Conclusion: We found no evidence that beta-blocker use was unsafe or associated with worse pulmonary outcomes in study participants with moderate to severe COPD.

Keywords: Beta-blocker; COPD; Exacerbation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Panel (a) - Percent free of exacerbation by beta-blocker use in the Macro placebo arm at 0, 30, 60, 90 and 180 days. Panel (b) – Percent free of exacerbation by beta-blocker use in the STATCOPE trial
See this image and copyright information in PMC

References

    1. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4 years trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554. doi: 10.1056/NEJMoa0805800. - DOI - PubMed
    1. Calverly PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med. 2007;356:775–789. doi: 10.1056/NEJMoa063070. - DOI - PubMed
    1. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Eng J Med. 2014;370:2201–10. doi: 10.1056/NEJMoa1403086. - DOI - PMC - PubMed
    1. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–98. doi: 10.1056/NEJMoa1104623. - DOI - PMC - PubMed
    1. JNC VI. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–46. doi: 10.1001/archinte.1997.00440420033005. - DOI - PubMed

Publication types

Substances